Business Context and Reporting Period
This Form 8-K was filed by Platform Specialty Products Corporation on December 2, 2014. The report details an amendment to a previously disclosed Share Purchase Agreement regarding the acquisition of Arysta LifeScience Limited.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The primary financial data relates to the transaction structure:
- Total Acquisition Value: Approximately $3.51 billion.
- Cash Component: $2.91 billion (subject to working capital and other adjustments).
- Equity Component: $600 million in new Series B convertible preferred stock.
Material Changes
The material change reported is an amendment to the acquisition agreement entered into on December 2, 2014. The key modification concerns the redemption terms of the Series B Convertible Preferred Stock:
- Previous Terms: Platform had the option to pay the redemption price at maturity in either cash or shares of common stock.
- New Terms: The redemption price must be paid exclusively in shares of Platform's common stock.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the transaction details. The document notes that the summary of the amendment is qualified by reference to the full text of the Amendment Agreement attached as Exhibit 2.1.
Investor Verification Checklist
- Verify the full text of the Amendment Agreement (Exhibit 2.1) to confirm all terms regarding the Series B Convertible Preferred Stock.
- Confirm the status of the $2.91 billion cash component and any working capital adjustments.
- Review the impact of the mandatory stock redemption on Platform's future capital structure and dilution.
- Check for any subsequent filings regarding the closing of the Arysta LifeScience Limited acquisition.